Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury

Bibliography

• National Spinal Cord Injury Statistical Center. Spinal cord injury facts and figures at a glance. J Spinal Cord Med 2010;33(4):439-40
   PubMedGoogle Scholar
• Kwon BK, Sekhon LH, Fehlings MG. Emerging repair, regeneration, and translational research advances for spinal cord injury. Spine 2010;35(21 Suppl):S263-70
   Web of Science ®Google Scholar
• Lim G, Wang S, Zeng Q, Spinal glucocorticoid receptors contribute to the development of morphine tolerance in rats. Anesthesiology 2005;102:832-7
   PubMed Web of Science ®Google Scholar
• Hurlbert RJ. Strategies of medical intervention in the management of acute spinal cord injury. Spine 2006;31(11 Suppl):S16-21; discussion S36
   Web of Science ®Google Scholar
• Cuzzocrea S. Peroxisome proliferator-activated receptors and acute lung injury. Curr Opin Pharmacol 2006;6:263-70
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 2005;103:1-9
   PubMed Web of Science ®Google Scholar
• Lee CH, Olson P, Hevener A, PPARDelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006;103:3444-9
   PubMed Web of Science ®Google Scholar
• Kilgore KS, Billin AN. PPARbeta/delta ligands as modulators of the inflammatory response. Curr Opin Investig Drugs 2008;9:463-9
   PubMed Web of Science ®Google Scholar
• Popovich PG, Stuckman S, Gienapp IE, Whitacre CC. Alterations in immune cell phenotype and function after experimental spinal cord injury. J Neurotrauma 2001;18:957-66
   PubMed Web of Science ®Google Scholar
• Dusart I, Schwab ME. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci 1994;6:712-24
   PubMed Web of Science ®Google Scholar
• Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997;377:443-64
   PubMed Web of Science ®Google Scholar
• Ahn YH, Lee G, Kang SK. Molecular insights of the injured lesions of rat spinal cords: Inflammation, apoptosis, and cell survival. Biochem Biophys Res Commun 2006;348:560-70
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Glaser J, Liu MT, Reducing inflammation decreases secondary degeneration and functional deficit after spinal cord injury. Exp Neurol 2003;184:456-63
   PubMed Web of Science ®Google Scholar
• Bartholdi D, Schwab ME. Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci 1997;9:1422-38
   PubMed Web of Science ®Google Scholar
• Glaser J, Gonzalez R, Perreau VM, Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury. J Neurosci Res 2004;77:701-8
   PubMed Web of Science ®Google Scholar
• Rice T, Larsen J, Rivest S, Yong VW. Characterization of the early neuroinflammation after spinal cord injury in mice. J Neuropathol Exp Neurol 2007;66:184-95
   PubMed Web of Science ®Google Scholar
• Hu R, Zhou J, Luo C, Glial scar and neuroregeneration: histological, functional, and magnetic resonance imaging analysis in chronic spinal cord injury. J Neurosurg Spine 2010;13:169-80
   PubMed Web of Science ®Google Scholar
• Beck KD, Nguyen HX, Galvan MD, Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 2010;133:433-47
   PubMed Web of Science ®Google Scholar
• Schnell L, Fearn S, Klassen H, Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur J Neurosci 1999;11:3648-58
   PubMed Web of Science ®Google Scholar
• Pollard ME, Apple DF. Factors associated with improved neurologic outcomes in patients with incomplete tetraplegia. Spine 2003;28:33-9
   PubMed Web of Science ®Google Scholar
• Hall ED, Springer JE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004;1:80-100
   PubMedGoogle Scholar
• Amar AP, Levy ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 1999;44:1027-39; discussion 1039-1040
   PubMed Web of Science ®Google Scholar
• Bracken MB, Collins WF, Freeman DF, Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984;251:45-52
   PubMed Web of Science ®Google Scholar
• Bracken MB, Shepard MJ, Holford TR, Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the third national acute spinal cord injury randomized controlled trial. National Acute Spinal Cord Injury Study. JAMA 1997;277:1597-604
   PubMed Web of Science ®Google Scholar
• Bracken MB, Shepard MJ, Holford TR, Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 1998;89:699-706
   PubMed Web of Science ®Google Scholar
• Fehlings MG. Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy. Spine 2001;26(24 Suppl):S56-7
   Web of Science ®Google Scholar
• Gorio A, Gokmen N, Erbayraktar S, Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002;99:9450-5
   PubMed Web of Science ®Google Scholar
• King VR, Averill SA, Hewazy D, Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 2007;26:90-100
   PubMed Web of Science ®Google Scholar
• Stahel PF, Barnum SR. The role of the complement system in CNS inflammatory diseases. Expert Rev Clin Immunol 2006;2:445-56
   PubMedGoogle Scholar
• Leinhase I, Rozanski M, Harhausen D, Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J Neuroinflammation 2007;4:13
   PubMed Web of Science ®Google Scholar
• Qiao F, Atkinson C, Kindy MS, The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am J Pathol 2010;177:3061-70
   PubMed Web of Science ®Google Scholar
• Mortazavi MM, Verma K, Tubbs RS, Theodore N. Cellular and paracellular transplants for spinal cord injury: a review of the literature. Childs Nerv Syst 2011;27:237-43
   PubMed Web of Science ®Google Scholar
• Dadsetan M, Knight AM, Lu L, Stimulation of neurite outgrowth using positively charged hydrogels. Biomaterials 2009;30:3874-81
   PubMed Web of Science ®Google Scholar
• Neville CM, Huang AY, Shyu JY, Neural precursor cell lines promote neurite branching. Int J Neurosci 2009;119:15-39
   PubMed Web of Science ®Google Scholar
• Pellitteri R, Spatuzza M, Russo A, Stanzani S. Olfactory ensheathing cells exert a trophic effect on the hypothalamic neurons in vitro. Neurosci Lett 2007;417:24-9
   PubMed Web of Science ®Google Scholar
• Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 1993;32:5598-604
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Brkanac Z, Dupont BR, Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21.1-p21.2. Genomics 1996;35:637-8
   PubMed Web of Science ®Google Scholar
• Braissant O, Foufelle F, Scotto C, Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354-66
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Hu E, Graves RA, mPPARgamma2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-34
   PubMed Web of Science ®Google Scholar
• Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 1998;139:2748-54
   PubMed Web of Science ®Google Scholar
• Inoue I, Shino K, Noji S, Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998;246:370-4
   PubMed Web of Science ®Google Scholar
• Marx N, Bourcier T, Sukhova GK, PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999;19:546-51
   PubMed Web of Science ®Google Scholar
• Chinetti G, Griglio S, Antonucci M, Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-80
   PubMed Web of Science ®Google Scholar
• Ricote M, Li AC, Willson TM, The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82
   PubMed Web of Science ®Google Scholar
• Marx N, Sukhova G, Murphy C, Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17-23
   PubMed Web of Science ®Google Scholar
• Chinetti G, Gbaguidi FG, Griglio S, CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000;101:2411-17
   PubMed Web of Science ®Google Scholar
• IJpenberg A, Jeannin E, Wahli W, Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 1997;272:20108-17
   PubMed Web of Science ®Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-35
   PubMed Web of Science ®Google Scholar
• McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002;108:465-74
   PubMed Web of Science ®Google Scholar
• Pascual G, Glass CK. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 2006;17:321-7
   PubMed Web of Science ®Google Scholar
• Horlein AJ, Naar AM, Heinzel T, Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995;377:397-404
   PubMed Web of Science ®Google Scholar
• Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-7
   PubMed Web of Science ®Google Scholar
• Hoberg JE, Yeung F, Mayo MW. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell 2004;16:245-55
   PubMed Web of Science ®Google Scholar
• Nolte RT, Wisely GB, Westin S, Ligand binding co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998;395:137-43
   PubMed Web of Science ®Google Scholar
• Perissi V, Aggarwal A, Glass CK, A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004;116:511-26
   PubMed Web of Science ®Google Scholar
• Pascual G, Fong AL, Ogawa S, A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437:759-63
   PubMed Web of Science ®Google Scholar
• Lee CH, Chawla A, Urbiztondo N, Transcriptional repression of atherogenic inflammation: modulation by PPARDelta. Science 2003;302:453-7
   PubMed Web of Science ®Google Scholar
• Chung SW, Kang BY, Kim SH, Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappaB. J Biol Chem 2000;275:32681-7
   PubMed Web of Science ®Google Scholar
• Ramanan S, Kooshki M, Zhao W, PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic Biol Med 2008;45:1695-704
   PubMed Web of Science ®Google Scholar
• Alleva DG, Johnson EB, Lio FM, Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma. J Leukoc Biol 2002;71:677-85
   PubMed Web of Science ®Google Scholar
• Zingarelli B, Sheehan M, Hake PW, Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 2003;171:6827-37
   PubMed Web of Science ®Google Scholar
• Yang XY, Wang LH, Chen T, Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000;275:4541-4
   PubMed Web of Science ®Google Scholar
• Cunard R, Eto Y, Muljadi JT, Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J Immunol 2004;172:7530-6
   PubMed Web of Science ®Google Scholar
• Kelly D, Campbell JI, King TP, Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004;5:104-12
   PubMed Web of Science ®Google Scholar
• Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat 2003;71:1-22
   PubMed Web of Science ®Google Scholar
• Cimini A, Benedetti E, Cristiano L, Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 2005;130:325-37
   PubMed Web of Science ®Google Scholar
• Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004;123:131-45
   PubMed Web of Science ®Google Scholar
• Churi SB, Abdel-Aleem OS, Tumber KK, Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain 2008;9:639-49
   PubMed Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50
   PubMed Web of Science ®Google Scholar
• Bernardo A, Ajmone-Cat MA, Levi G, Minghetti L. 15-deoxy-Delta12,14-prostaglandin J2 regulates the functional state and the survival of microglial cells through multiple molecular mechanisms. J Neurochem 2003;87:742-51
   PubMed Web of Science ®Google Scholar
• Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61
   PubMed Web of Science ®Google Scholar
• Ziouzenkova O, Perrey S, Asatryan L, Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 2003;100:2730-5
   PubMed Web of Science ®Google Scholar
• Fitzpatrick FA, Wynalda MA. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J Biol Chem 1983;258:11713-18
   PubMed Web of Science ®Google Scholar
• Forman BM, Tontonoz P, Chen J, 15-Deoxy-Delta12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83:803-12
   PubMed Web of Science ®Google Scholar
• Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol 2005;114:100-9
   PubMed Web of Science ®Google Scholar
• Wolf G. Adipocyte differentiation is regulated by a prostaglandin liganded to the nuclear peroxisome proliferator-activated receptor. Nutr Rev 1996;54:290-2
   PubMed Web of Science ®Google Scholar
• Genovese T, Cuzzocrea S, Di Paola R, Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005;25:225-34
   PubMed Web of Science ®Google Scholar
• Boyault S, Bianchi A, Moulin D, 15-Deoxy-Delta12,14-prostaglandin J2 inhibits IL-1beta-induced IKK enzymatic activity and IkappaBalpha degradation in rat chondrocytes through a PPARgamma-independent pathway. FEBS Lett 2004;572:33-40
   PubMed Web of Science ®Google Scholar
• Cheatham WW. Peroxisome proliferator-activated receptor translational research and clinical experience. Am J Clin Nutr 2010;91:262S-6S
   PubMed Web of Science ®Google Scholar
• Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004;25:899-918
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Garg A. Genetic basis of lipodystrophies and management of metabolic complications. Annu Rev Med 2006;57:297-311
   PubMed Web of Science ®Google Scholar
• Simo R, Rodriguez A, Caveda E. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Curr Drug Saf 2010;5:234-44
   PubMedGoogle Scholar
• Krishnaswami A, Ravi-Kumar S, Lewis JM. Thiazolidinediones: a 2010 perspective. Perm J 2010;14:64-72
   PubMedGoogle Scholar
• Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 2010;210:35-40
   PubMed Web of Science ®Google Scholar
• Leibowitz MD, Fievet C, Hennuyer N, Activation of PPARDelta alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-6
   PubMed Web of Science ®Google Scholar
• Hall JM, McDonnell DP. The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. Mol Endocrinol 2007;21:1756-68
   PubMedGoogle Scholar
• Gonzalez FJ. Recent update on the PPARalpha-null mouse. Biochimie 1997;79:139-44
   PubMed Web of Science ®Google Scholar
• Cunard R, Ricote M, DiCampli D, Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 2002;168:2795-802
   PubMed Web of Science ®Google Scholar
• Delerive P, De Bosscher K, Besnard S, Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999;274:32048-54
   PubMed Web of Science ®Google Scholar
• Kockx M, Gervois PP, Poulain P, Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 1999;93:2991-8
   PubMed Web of Science ®Google Scholar
• Madej A, Okopien B, Kowalski J, Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998;36:345-9
   PubMed Web of Science ®Google Scholar
• Lovett-Racke AE, Hussain RZ, Northrop S, Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004;172:5790-8
   PubMed Web of Science ®Google Scholar
• Cunard R, DiCampli D, Archer DC, WY14,643, a PPARalpha ligand, has profound effects on immune responses in vivo. J Immunol 2002;169:6806-12
   PubMed Web of Science ®Google Scholar
• Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998;273:32833-41
   PubMed Web of Science ®Google Scholar
• Gocke AR, Hussain RZ, Yang Y, Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-alpha agonists in autoimmune disease. J Immunol 2009;182:4479-87
   PubMed Web of Science ®Google Scholar
• Li AC, Binder CJ, Gutierrez A, Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/Delta, and gamma. J Clin Invest 2004;114:1564-76
   PubMed Web of Science ®Google Scholar
• Berry A, Balard P, Coste A, IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. Eur J Immunol 2007;37:1642-52
   PubMed Web of Science ®Google Scholar
• Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 2005;12:2995-3009
   PubMed Web of Science ®Google Scholar
• Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr Pharm Des 2004;10:3505-24
   PubMed Web of Science ®Google Scholar
• Shie FS, Nivison M, Hsu PC, Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma. Curr Med Chem 2009;16:643-51
   PubMed Web of Science ®Google Scholar
• Sundararajan S, Jiang Q, Heneka M, Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 2006;49:136-44
   PubMed Web of Science ®Google Scholar
• Haffner SM, Greenberg AS, Weston WM, Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84
   PubMed Web of Science ®Google Scholar
• Setoguchi K, Misaki Y, Terauchi Y, Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest 2001;108:1667-75
   PubMed Web of Science ®Google Scholar
• Barish GD, Downes M, Alaynick WA, A Nuclear Receptor Atlas: macrophage activation. Mol Endocrinol 2005;19:2466-77
   PubMed Web of Science ®Google Scholar
• Marx N, Schonbeck U, Lazar MA, Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83:1097-103
   PubMed Web of Science ®Google Scholar
• Murao K, Imachi H, Momoi A, Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 1999;454:27-30
   PubMed Web of Science ®Google Scholar
• Clark RB, Bishop-Bailey D, Estrada-Hernandez T, The nuclear receptor PPARgamma and immunoregulation: PPARgamma mediates inhibition of helper T cell responses. J Immunol 2000;164:1364-71
   PubMed Web of Science ®Google Scholar
• Zapata-Gonzalez F, Rueda F, Petriz J, Human dendritic cell activities are modulated by the omega-3 fatty acid, docosahexaenoic acid, mainly through PPARgamma:RXR heterodimers: comparison with other polyunsaturated fatty acids. J Leukoc Biol 2008;84:1172-82
   PubMed Web of Science ®Google Scholar
• Straus DS, Pascual G, Li M, 15-deoxy-Delta12,14-prostaglandin J2 inhibits multiple steps in the NF-kappaB signaling pathway. Proc Natl Acad Sci USA 2000;97:4844-9
   PubMed Web of Science ®Google Scholar
• Chawla A, Barak Y, Nagy L, PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52
   PubMed Web of Science ®Google Scholar
• Welch JS, Ricote M, Akiyama TE, PPARgamma and PPARDelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA 2003;100:6712-17
   PubMed Web of Science ®Google Scholar
• Dunn SE, Bhat R, Straus DS, Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med 2010;207:1599-608
   PubMed Web of Science ®Google Scholar
• Desvergne B. PPARDelta/beta: the lobbyist switching macrophage allegiance in favor of metabolism. Cell Metab 2008;7:467-9
   PubMed Web of Science ®Google Scholar
• Barish GD, Atkins AR, Downes M, PPARDelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci USA 2008;105:4271-6
   PubMed Web of Science ®Google Scholar
• Ding G, Cheng L, Qin Q, PPARDelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 2006;40:821-8
   PubMed Web of Science ®Google Scholar
• Kharroubi I, Lee CH, Hekerman P, BCL-6: a possible missing link for anti-inflammatory PPAR-Delta signalling in pancreatic beta cells. Diabetologia 2006;49:2350-8
   PubMed Web of Science ®Google Scholar
• Bouhlel MA, Brozek J, Derudas B, Unlike PPARgamma, PPARalpha or PPARbeta/Delta activation does not promote human monocyte differentiation toward alternative macrophages. Biochem Biophys Res Commun 2009;386:459-62
   PubMed Web of Science ®Google Scholar
• Kang K, Reilly SM, Karabacak V, Adipocyte-derived Th2 cytokines and myeloid PPARDelta regulate macrophage polarization and insulin sensitivity. Cell Metab 2008;7:485-95
   PubMed Web of Science ®Google Scholar
• Xu J, Storer PD, Chavis JA, Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res 2005;81:403-11
   PubMed Web of Science ®Google Scholar
• Bernardo A, Levi G, Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12,14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 2000;12:2215-23
   PubMed Web of Science ®Google Scholar
• Szeles L, Torocsik D, Nagy L. PPARgamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 2007;1771:1014-30
   PubMed Web of Science ®Google Scholar
• Luconi M, Cantini G, Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer? Steroids 2010;75:585-94
   PubMed Web of Science ®Google Scholar
• Malaspina A, Turkheimer F. A review of the functional role and of the expression profile of retinoid signaling and of nuclear receptors in human spinal cord. Brain Res Bull 2007;71:437-46
   PubMed Web of Science ®Google Scholar
• Malaspina A, Michael-Titus AT. Is the modulation of retinoid and retinoid-associated signaling a future therapeutic strategy in neurological trauma and neurodegeneration? J Neurochem 2008;104:584-95
   PubMed Web of Science ®Google Scholar
• Bregman BS, Diener PS, McAtee M, Intervention strategies to enhance anatomical plasticity and recovery of function after spinal cord injury. Adv Neurol 1997;72:257-75
   PubMedGoogle Scholar
• Yi JH, Park SW, Brooks N, PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 2008;1244:164-72
   PubMed Web of Science ®Google Scholar
• Genovese T, Esposito E, Mazzon E, Effect of cyclopentanone prostaglandin 15-deoxy-Delta12,14PGJ2 on early functional recovery from experimental spinal cord injury. Shock 2008;30:142-52
   PubMed Web of Science ®Google Scholar
• McTigue DM, Tripathi R, Wei P, Lash AT. The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol 2007;205:396-406
   PubMed Web of Science ®Google Scholar
• Park SW, Yi JH, Miranpuri G, Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007;320:1002-12
   PubMed Web of Science ®Google Scholar
• Zhang Q, Hu W, Meng B, Tang T. PPARgamma agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res 2010;32:852-9
   PubMed Web of Science ®Google Scholar
• Churi SB, Abdel-Aleem OS, Tumber KK, Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain 2008;9:639-49
   PubMed Web of Science ®Google Scholar
• Maeda T, Kiguchi N, Kobayashi Y, Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008;108:341-7
   PubMed Web of Science ®Google Scholar
• Morgenweck J, Abdel-Aleem OS, McNamara KC, Activation of peroxisome proliferator-activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology 2010;58:337-45
   PubMed Web of Science ®Google Scholar
• McTigue DM. Potential therapeutic targets for PPARgamma after spinal cord injury. PPAR Res 2008;2008:517162
   PubMed Web of Science ®Google Scholar
• van Neerven S, Mey J. RAR/RXR and PPAR/RXR signaling in spinal cord injury. PPAR Res 2007;2007:29275
   PubMed Web of Science ®Google Scholar
• Cuzzocrea S, Di Paola R, Mazzon E, Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab Invest 2004;84:1643-54
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Krone W. Peroxisome proliferator-activated receptor alpha (PPAR-alpha) and athero-sclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:513-23
   PubMedGoogle Scholar
• Colville-Nash P, Willis D, Papworth J, The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo. Inflammopharmacology 2005;12:493-504
   PubMedGoogle Scholar
• Genovese T, Mazzon E, Di Paola R, Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. Exp Neurol 2005;194:267-78
   PubMed Web of Science ®Google Scholar
• Genovese T, Esposito E, Mazzon E, PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacol Res 2009;59:338-50
   PubMed Web of Science ®Google Scholar
• Lo Verme J, Fu J, Astarita G, The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67:15-19
   PubMed Web of Science ®Google Scholar
• Genovese T, Esposito E, Mazzon E, Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 2008;326:12-23
   PubMed Web of Science ®Google Scholar
• Almad A, McTigue DM. Chronic expression of PPAR-Delta by oligodendrocyte lineage cells in the injured rat spinal cord. J Comp Neurol 2010;518:785-99
   PubMed Web of Science ®Google Scholar
• Paterniti I, Esposito E, Mazzon E, Evidence for the role of peroxisome proliferator-activated receptor-beta/Delta in the development of spinal cord injury. J Pharmacol Exp Ther 2010;333:465-77
   PubMed Web of Science ®Google Scholar
• Iwashita A, Muramatsu Y, Yamazaki T, Neuroprotective efficacy of the peroxisome proliferator-activated receptor Delta-selective agonists in vitro and in vivo. J Pharmacol Exp Ther 2007;320:1087-96
   PubMed Web of Science ®Google Scholar
• Chan CC. Inflammation: beneficial or detrimental after spinal cord injury? Recent Pat CNS Drug Discov 2008;3:189-99
   PubMedGoogle Scholar
• Esposito E, Cuzzocrea S. Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci 2011;32:107-15
   PubMed Web of Science ®Google Scholar
• Renault-Mihara F, Okada S, Shibata S, Spinal cord injury: emerging beneficial role of reactive astrocytes' migration. Int J Biochem Cell Biol 2008;40:1649-53
   PubMed Web of Science ®Google Scholar
• Sauerbeck A, Gao J, Readnower R, Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 2011;227:128-35
   PubMed Web of Science ®Google Scholar